Chronix news

Chronix notes abstract disclosure for forthcoming ASCO presentation. Head and neck cancer study finds CNI score to be a stronger predictor of time to recurrence than current method based on lymph node invasion.

The poster presentation is entitled Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer.

It presents data from a study that examined copy number instability (CNI) in circulating tumour DNA from 54 patients undergoing surgery for head and neck cancer and compared the Chronix CNI-based test as a predictor of time to progression with the current method based on the degree of tumour invasion of lymph nodes (pN status).

Chronix Biomedical is pleased to announce that results of a clinical trial of its liquid biopsy test have been accepted for presentation at the ASCO Annual Meeting.

Chronix Biomedical

The poster presentation will cover results of a study evaluating the Copy Number Instability (CNI) score as a prognostic test in head and neck cancer.

Chronix Biomedical Study Demonstrates Its Blood Test Can Predict Response to Cancer Immunotherapy

Chronix Biomedical

First study of a liquid biopsy to predict response to immunotherapy...

Chronix Biomedical provides update on studies and presentations

Chronix Biomedical

Data from pilot studies using Chronix’s CNI test submitted for presentation at a high profile scientific meeting...

10 Cancer Symptoms

Chronix Biomedical

The best way to fight cancer is to diagnose it in its early stage...

WORLD CANCER DAY

Chronix Biomedical

World Cancer Day is a perfect opportunity to focus on your health state...